title: A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation.
abstract: BACKGROUND
  Since dopaminergic mechanisms appear to be involved in nicotine dependence, we studied the safety and efficacy of the monoamine oxidase B inhibitor selegiline hydrochloride compared with placebo for smoking cessation in nicotine-dependent cigarette smokers.
  
  
  METHODS
  Forty subjects with DSM-IV nicotine dependence were randomized to: 1) selegiline hydrochloride (5 mg p.o. twice daily) or 2) placebo in an 8-week trial. Outcome measures included smoking cessation rates, treatment retention, and medication side effects.
  
  
  RESULTS
  Selegiline hydrochloride increased trial end point (week 8) 7-day point prevalence smoking cessation rates (selegiline hydrochloride, 9/20 [45.0%]; placebo, 3/20 [15.0%], odds ratio = 4.64, 95% CI, 1.02-21.00, p <.05), and smoking cessation rates during the last 4 weeks of the trial (selegiline hydrochloride, 6/20 [30.0%]; placebo, 1/20 [5.0%], odds ratio = 8.14, 95% CI, 0.88-75.48, p =.07) in comparison with placebo. Six-month follow-up 7-day point prevalence smoking cessation rates were reduced compared with trial end point (selegiline hydrochloride, 4/20 [20.0%]; placebo, 1/20 [5.0%], odds ratio = 4.75, 95% CI, 0.48-46.91, p =.18). Treatment retention was similar between drug and placebo groups (p =.13), and selegiline hydrochloride was well tolerated in cigarette smokers.
  
  
  CONCLUSIONS
  This preliminary study suggests that selegiline (10 mg/day) is safe for use and enhances smoking cessation rates compared with placebo in nicotine-dependent cigarette smokers.
authors.affiliation: Program for Research in Smokers with Mental Illness (PRISM), New Haven, Connecticut 06519, USA.
authors.forename: Tony P
authors.initials: TP
authors.lastname: George
authors.forename: Jennifer C
authors.initials: JC
authors.lastname: Vessicchio
authors.forename: Angelo
authors.initials: A
authors.lastname: Termine
authors.forename: Peter I
authors.initials: PI
authors.lastname: Jatlow
authors.forename: Thomas R
authors.initials: TR
authors.lastname: Kosten
authors.forename: Stephanie S
authors.initials: SS
authors.lastname: O'Malley
mesh_terms: D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D016017:Odds Ratio; D012642:Selegiline / Q000627:therapeutic use*; D012907:Smoking / Q000188:drug therapy*; D016540:Smoking Cessation; D013997:Time Factors
chemical_list: D008996:Monoamine Oxidase Inhibitors; D012642:Selegiline